366 related articles for article (PubMed ID: 20154217)
1. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Koppikar P; Abdel-Wahab O; Hedvat C; Marubayashi S; Patel J; Goel A; Kucine N; Gardner JR; Combs AP; Vaddi K; Haley PJ; Burn TC; Rupar M; Bromberg JF; Heaney ML; de Stanchina E; Fridman JS; Levine RL
Blood; 2010 Apr; 115(14):2919-27. PubMed ID: 20154217
[TBL] [Abstract][Full Text] [Related]
2. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
3. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
[TBL] [Abstract][Full Text] [Related]
4. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.
Wernig G; Kharas MG; Mullally A; Leeman DS; Okabe R; George T; Clary DO; Gilliland DG
Leukemia; 2012 Apr; 26(4):720-7. PubMed ID: 22005786
[TBL] [Abstract][Full Text] [Related]
5. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
[TBL] [Abstract][Full Text] [Related]
6. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
7. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Tyner JW; Bumm TG; Deininger J; Wood L; Aichberger KJ; Loriaux MM; Druker BJ; Burns CJ; Fantino E; Deininger MW
Blood; 2010 Jun; 115(25):5232-40. PubMed ID: 20385788
[TBL] [Abstract][Full Text] [Related]
8. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
[TBL] [Abstract][Full Text] [Related]
9. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
10. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.
Majumder A; Govindasamy L; Magis A; Kiss R; Polgár T; Baskin R; Allan RW; Agbandje-McKenna M; Reuther GW; Keseru GM; Bisht KS; Sayeski PP
J Biol Chem; 2010 Oct; 285(41):31399-407. PubMed ID: 20667821
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic resistance to JAK2 inhibition in myelofibrosis.
Kalota A; Jeschke GR; Carroll M; Hexner EO
Clin Cancer Res; 2013 Apr; 19(7):1729-39. PubMed ID: 23386690
[TBL] [Abstract][Full Text] [Related]
12. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
[TBL] [Abstract][Full Text] [Related]
13. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
14. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
Spivak JL
Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
[TBL] [Abstract][Full Text] [Related]
15. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Pomicter AD; Eiring AM; Senina AV; Zabriskie MS; Marvin JE; Prchal JT; O'Hare T; Deininger MW
Exp Hematol; 2015 Jul; 43(7):537-45.e1-11. PubMed ID: 25912019
[TBL] [Abstract][Full Text] [Related]
16. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
[TBL] [Abstract][Full Text] [Related]
17. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
18. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.
O'Sullivan JM; Harrison CN
Mol Cell Endocrinol; 2017 Aug; 451():71-79. PubMed ID: 28167129
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
Pecquet C; Diaconu CC; Staerk J; Girardot M; Marty C; Royer Y; Defour JP; Dusa A; Besancenot R; Giraudier S; Villeval JL; Knoops L; Courtoy PJ; Vainchenker W; Constantinescu SN
Blood; 2012 May; 119(20):4625-35. PubMed ID: 22378845
[TBL] [Abstract][Full Text] [Related]
20. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Meyer SC; Keller MD; Chiu S; Koppikar P; Guryanova OA; Rapaport F; Xu K; Manova K; Pankov D; O'Reilly RJ; Kleppe M; McKenney AS; Shih AH; Shank K; Ahn J; Papalexi E; Spitzer B; Socci N; Viale A; Mandon E; Ebel N; Andraos R; Rubert J; Dammassa E; Romanet V; Dölemeyer A; Zender M; Heinlein M; Rampal R; Weinberg RS; Hoffman R; Sellers WR; Hofmann F; Murakami M; Baffert F; Gaul C; Radimerski T; Levine RL
Cancer Cell; 2015 Jul; 28(1):15-28. PubMed ID: 26175413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
